These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21870713)

  • 1. [The alteration of proteins glycosylation in liver diseases].
    Chrostek L; Cylwik B
    Pol Merkur Lekarski; 2011 Jul; 31(181):60-4. PubMed ID: 21870713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of protein glycosylation in liver diseases.
    Blomme B; Van Steenkiste C; Callewaert N; Van Vlierberghe H
    J Hepatol; 2009 Mar; 50(3):592-603. PubMed ID: 19157620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and humans.
    Blomme B; Van Steenkiste C; Vanhuysse J; Colle I; Callewaert N; Van Vlierberghe H
    Am J Physiol Gastrointest Liver Physiol; 2010 May; 298(5):G615-24. PubMed ID: 20056895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-bound sialic acid (LSA) in liver diseases of different etiologies.
    Chrostek L; Cylwik B; Panasiuk A; Brodowska-Adamusiak D; Gruszewska E
    Ann Hepatol; 2011; 10(2):150-4. PubMed ID: 21502676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases.
    Anderson N; Pollacchi A; Hayes P; Therapondos G; Newsome P; Boyter A; Smith K
    Biomed Chromatogr; 2002 Sep; 16(6):365-72. PubMed ID: 12228891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of various types of liver diseases on the behavior of cefoperazone].
    Malè PJ; Dayer P; Châtelain G; Rudhardt M; Fabre J
    Schweiz Med Wochenschr; 1983 Dec; 113(49):1860-3. PubMed ID: 6676938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The behavior of albumin in acute and chronic liver damage. III. Intrahepatic and serum albumin concentrations in human liver diseases].
    Rogos R
    Z Gesamte Inn Med; 1978 Aug; 33(15):506-12. PubMed ID: 695790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The liver and circulating thyroid hormones.
    Klachko DM; Johnson ER
    J Clin Gastroenterol; 1983 Oct; 5(5):465-71. PubMed ID: 6313798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thyroid gland and thyroid status in patients with chronic liver diseases].
    Podymova SD; Ulanova IN; Bolśhakova TD; Khomiakova VN
    Klin Med (Mosk); 1997; 75(3):32-5. PubMed ID: 9229611
    [No Abstract]   [Full Text] [Related]  

  • 10. Proteomics in the study of liver pathology.
    Parent R; Beretta L
    J Hepatol; 2005 Jul; 43(1):177-83. PubMed ID: 15894398
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell surface protein glycosylation in cancer.
    Christiansen MN; Chik J; Lee L; Anugraham M; Abrahams JL; Packer NH
    Proteomics; 2014 Mar; 14(4-5):525-46. PubMed ID: 24339177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hematologic masks in liver diseases].
    Tentsova IA
    Probl Gematol Pereliv Krovi; 1981 Jun; 26(6):43-7. PubMed ID: 6792623
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum gamma-glutamyl transpeptidase: its clinical significance.
    Pár A; Mestyán I; Kádas I; Balázs M; Gógl A
    Acta Med Acad Sci Hung; 1976; 33(4):309-19. PubMed ID: 23644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis.
    Cheung KJ; Libbrecht L; Tilleman K; Deforce D; Colle I; Van Vlierberghe H
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1066-73. PubMed ID: 20186066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on expression of P16 protein in the liver tissue of viral hepatitis].
    Xin S; Wang L; Wang S
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):122-4. PubMed ID: 12515187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of host factors on drug response. VI. Hepatocellular diseases.
    Vesell ES
    Ration Drug Ther; 1981 Aug; 15(8):1-8. PubMed ID: 7347855
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic diseases in the elderly.
    Van Dam J; Zeldis JB
    Gastroenterol Clin North Am; 1990 Jun; 19(2):459-72. PubMed ID: 2163984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fucosylated glycoproteins as markers of liver disease.
    Mehta A; Block TM
    Dis Markers; 2008; 25(4-5):259-65. PubMed ID: 19126969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of precursors into sterols and proteins in liver biopsies from patients with liver disorders.
    Evensen SA; Ritland S; Elgjo K; Solberg HE; Skrede S
    Scand J Gastroenterol; 1984 Jan; 19(1):6-13. PubMed ID: 6143395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic and blood lead levels in patients with chronic liver disease.
    Castilla L; Castro M; Grilo A; Guerrero P; Lopez-Artiguez M; Soria ML; Martinez-Parra D
    Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):243-9. PubMed ID: 7743306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.